沙丁胺醇联合异丙托溴铵雾化吸入治疗慢性阻塞性肺疾病的效果分析  

Analysis of the effect of salbutamol combined with ipratropium bromide aerosol inhalation in the treatment of chronic obstructive pulmonary disease

作　　者：赵丽娜 ZHAO Li-na(Second Respiratory Department,Panjin Central Hospital,Panjin 124000,China)

机构地区：[1]盘锦市中心医院呼吸二科,124000

出　　处：《中国现代药物应用》2023年第2期16-20,共5页Chinese Journal of Modern Drug Application

摘　　要：目的分析沙丁胺醇联合异丙托溴铵雾化吸入治疗慢性阻塞性肺疾病的临床效果。方法94例慢性阻塞性肺疾病患者,根据用药方案不同分为对照组与观察组,各47例。对照组应用沙丁胺醇雾化吸入治疗,观察组应用沙丁胺醇联合异丙托溴铵雾化吸入治疗。比较两组雾化吸入前后的肺功能指标[用力肺活量(FVC)、第1秒用力呼气容积(FEV1)、第1秒用力呼气容积与用力肺活量的比值(FEV1/FVC)]、血气分析指标[氧分压(PaO_(2))、二氧化碳分压(PaCO_(2))、氧分压与吸入气氧浓度的比值(PaO_(2)/FiO_(2))]、呼吸困难程度[改良版呼吸困难指数(mMRC)评分]、病情严重程度[急性生理功能和慢性健康状况评分系统Ⅱ(APACHEⅡ)评分]及临床疗效、不良反应发生情况。结果雾化吸入后,观察组FVC(2.39±0.31)L、FEV1(1.75±0.51)L、FEV1/FVC(72.57±6.35)%均高于对照组的(2.14±0.37)L、(1.48±0.45)L、(66.18±6.23)%,差异有统计学意义(P<0.05)。雾化吸入后,观察组PaO_(2)(70.58±8.22)mm Hg(1 mm Hg=0.133 kPa)、PaO_(2)/FiO_(2)(267.28±37.58)高于对照组的(63.43±7.06)mm Hg、(230.17±34.73),PaCO_(2)(41.63±5.72)mm Hg低于对照组的(45.51±7.23)mm Hg,差异有统计学意义(P<0.05)。雾化吸入后,观察组mMRC评分(1.69±0.71)分低于对照组的(2.42±0.85)分,差异有统计学意义(P<0.05)。雾化吸入后,观察组APACHE II评分(14.06±2.26)分低于对照组的(18.42±2.95)分,差异有统计学意义(P<0.05)。观察组治疗总有效率95.74%高于对照组的82.98%,差异有统计学意义(P<0.05)。观察组不良反应发生率19.15%与对照组的14.89%比较,差异无统计学意义(P>0.05)。结论沙丁胺醇联合异丙托溴铵雾化吸入治疗慢性阻塞性肺疾病的效果显著,可改善患者的肺功能与血气分析指标,减轻呼吸困难症状与病情严重程度,且不增加不良反应,有效性与安全性均较好,值得推广。Objective To analyze the effect of salbutamol combined with ipratropium bromide aerosol inhalation in the treatment of chronic obstructive pulmonary disease.Methods A total of 94 patients with chronic obstructive pulmonary disease were divided into a control group and an observation group according to the different medication regimens,with 47 cases in each group.The control group was treated with salbutamol aerosol inhalation,and the observation group was treated with salbutamol combined with ipratropium bromide aerosol inhalation.Both groups were compared in terms of lung function indexes[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),FEV1/FVC],blood gas analysis indexes[arterial partial pressure of oxygen(PaO_(2)),arterial partial pressure of carbon dioxide(PaCO_(2)),PaO_(2)/inhaled oxygen concentration(FiO_(2))],degree of dyspnea[modified British Medical Research Council Dyspnea Scale(mMRC)score],severity of disease[Acute Physiology and Chronic Healthy EvaluationⅡ(APACHEⅡ)score],clinical efficacy,and occurrence of adverse reactions.Results After aerosol inhalation,the FVC(2.39±0.31)L,FEV1(1.75±0.51)L,and FEV1/FVC(72.57±6.35)%in the observation group were higher than(2.14±0.37)L,(1.48±0.45)L,and(66.18±6.23)%in the control group,and the differences were statistically significant(P<0.05).After aerosol inhalation,the PaO_(2)(70.58±8.22)mm Hg(1 mm Hg=0.133 kPa)and PaO_(2)/FiO_(2)(267.28±37.58)in the observation group were higher than(63.43±7.06)mm Hg and(230.17±34.73)in the control group;the PaCO_(2)(41.63±5.72)mm Hg in the observation group was lower than(45.51±7.23)mm Hg in the control group;the differences were statistically significant(P<0.05).After aerosol inhalation,the mMRC score of the observation group was(1.69±0.71)points,which was lower than(2.42±0.85)points of the control group,and the difference was statistically significant(P<0.05).After aerosol inhalation,the APACHEⅡscore of the observation group was(14.06±2.26)points,which was lower than(18.42±2.95)poin

关 键 词：慢性阻塞性肺疾病 沙丁胺醇 异丙托溴铵 雾化吸入 支气管舒张剂 

分 类 号：R563.9[医药卫生—呼吸系统]